Analytical tools for process and product characterization

BioPharm International

Volumn 22, Issue 8, 2009, Pages 32-44

  Kendrick, Brent S ^a   Chrimes, Greg ^a   Cockrill, Steven L ^a   Gabrielson, John P ^a   Arthur, Kelly K ^a   Prater, Brad D ^a   Qin, Qiang ^a   Zhang, Bing ^a   Rathore, Anurag S ^b  

^a AMGEN INC   (United States)

^b INDIAN INSTITUTE OF TECHNOLOGY DELHI   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; DISULFIDE; IMMUNOGLOBULIN G2; MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN;

ANALYTIC METHOD; BIOTECHNOLOGY; DISULFIDE BOND; DISULFIDE LINKAGE ANALYSIS; FLOW INJECTION ANALYSIS; GEL PERMEATION CHROMATOGRAPHY; GLYCAN ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH THROUGHPUT SCREENING; MASS SPECTROMETRY; PROCESS DESIGN; PROCESS TECHNOLOGY; PROTEIN ANALYSIS; QUALITY CONTROL; REVIEW; SEDIMENTATION RATE; ULTRACENTRIFUGATION;

EID: 77951638082     PISSN: 1542166X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Rathore AS, Winkle H. Quality by Design for pharmaceuticals: regulatory perspective and approach. Nature Biotechnol. 2009;27:26-34.
2. Rathore AS, Branning R, Cecchini D. Design space for biotech products. BioPharm Int. 2007;20(4):36-40. (Pubitemid 46658621)
3. Kozlowski S, Swann R Considerations for biotechnology product Quality by Design. Rathore AS, Mhatre R, editors. In Quality by Design for biopharmaceuticals: Perspectives and case studies. New Jersey: Wiley lnterscience; 2009. p. 9-30.
4. Swann PG, Tolnay M, Muthukkurnar S., Shapiro MA, Rellahan BL, Clouse KA. Considerations for the development of therapeutic monoclonal antibodies. Curr Opin Immunol. 2008;(42):493-99.
5. Towns J, Webber K. Demonstrating comparability for well-characterized biotechnology products. BioProcess Int. 2008;2:32-43.
6. Schnerman MA, Sunday BR, Kozlowski 5, Webber K, Gazzano-Santoro H, Mire-Sluis A. 0MG strategy forum report: analysis and structure characterization of monoclonal antibodies. BioProcess Int. 2004;(2):42-52.
7. International Conference on Harmonization. Q6B, Specifications: test procedures and acceptance criteria for biotechnological/biological products. Geneva, Switzerland; 1999.
8. Krull IS, Swartz M. Validation in biotechnology and well-characterized biopharmaceutical product. Pharmaceutical Regulatory Guidance Book. 2006;7:18-23.
9. Apostol I, Kelner D. Managing the analytical lifecycle for biotechnology products. BioProcess Int. Part 1: 2008;9:12-19. Part 2: 2008;(10):12-19.
10. Wu J, Watson iT. Assignment of disulfide bonds in proteins by chemical cleavage and peptide mapping by mass spectrometry. Methods Mol Biol. 2002;194:1-22.
11. Yen T-Y, Yan H, Macher BA. Characterizing closely-spaced, complex disulfide bond patterns in peptides and proteins by liquid chromatography/ electrospray ionization tandem mass spectrometry. J Mass Spectrorn. 2002;37:15-30. (Pubitemid 34130483)
12. Martinez T, Guo A, Allen Mi, Han M, Pace D, Jones i, et al. Disulfide connectivity of human immunoglobulin G2 structural isoforms. Biochem. 2008;47:7496-508. (Pubitemid 351991028)
13. Zhang W, Marzilli LA, Rouse JC, Czupryn MJ. Complete disulfide bond assignment of a recombinant immunoglobulin G4 monoclonal antibody. Anal Riochem. 2002;311:1-9. (Pubitemid 35463482)
14. Wypych J, Li M, Guo A, Zhang Z, Martinez I, Allen MJ, et al. Human lgG2 antibodies display disulfide-mediated structural isoforms. J Biol Chem. 2008:283:16194-205.
15. Cockrill SL. Complete determination of lgG2 disulfide connectivity: defining an analytical strategy for a new structural paradigm. Invited talk. IBC 12th Annual Well Characterized Biologicals Conference; 2008 Nov 10-12; Reston, VA.
16. European Commission (Enterprise Directorate General). EMEA Guideline on Production and Quality Control of Monoclonal Antibodies and Related Substances (Draft). Brussels, Belgium; 2008 Jul. Available from http://www.emea.europa.eu/ pdfs/human/bwp/15765307en.pdf.
17. Anumula KR. High-sensitivity and high resolution methods for glycoprotein analysis. Anal Biochem. 2000;283:17-26. (Pubitemid 30469745)
18. Chen X, Flynn GC, Analysis of N-glycans from recombinant immunoglobulin G by online reversed-phase high-performance liquid chromatography/mass spectrometry. Anal Biochem. 2007;370:147-61. (Pubitemid 47484317)
19. Prater BD, Anumula KR, Hutchins JT, Automated sample preparation facilitated by PhyNexus MEA purification system for oligosaccharide mapping of glycoproteins. Anal Biochem. 2007;369:202-09.
20. Prater BD, Connelly HM, Qin Q, Cockrill SL. High-throughput immunoglobulin G N-glycan characterization using rapid resolution reverse-phase chromatography tandem mass spectrometry. Anal Biochem. 2009;385:69-79.
21. Nguyen LT, WiencekiM, Kirsch LE. Characterization methods for the physical stability of biopharmaceuticals. PDA J Pharm Sci Technol. 2003;57:429-45.
22. Gabrielson JP, et al. Quantitation of aggregate levels in a recombinant humanized monoclonal antibody formulation by size-exclusion chromatography, asymmetrical flow field flow fractionation, and sedimentation velocity. J Pharm Sci. 2007;96(2):268-79.
23. Philo JS. Is any measurement method optimal for all aggregate sizes and types? AAPS i. 2006;8(3): E564-E571.
24. Arthur KK, et al. Detection of protein aggregates by sedimentation velocity analytical ultracentrifugation (SV-AUC): Sources of variability and their relative importance (p n/a). J Pharrn Sci. 2009;doi 10.1002/jps.21654.
25. Berkowitz SA. Role of analytical ultracentrifugation in assessing the aggregation of protein biopharmaceuticals. AAPS J. 2006;8(3):E590-605.
26. Liu J, Andya JD, Shire SJ. A critical review of analytical ultracentrifugation and field flow fractionation methods for measuring protein aggregation. AAPS i. 2006;8(3):E580-89.
27. Pekar A, Sukumar M. Quantitation of aggregates in therapeutic proteins using sedimentation velocity analytical ultracentrifugation: Practical considerations that affect precision and accuracy. Anal Biochem. 2007;367:225-37. (Pubitemid 47001925)
28. Gabrielson JP, et al. Common excipients impair detection of protein aggregates during sedimentation velocity analytical ultracentrifugation. i Pharm Sci. 2009;98(1):50-62.
29. Schuck R A model for sedimentation in inhomogeneous media. I. Dynamic density gradients from sedimenting co-solutes. Biophys Chem. 2004;108(1-3):187-200.
30. Schuck P, et al. Size-distribution analysis of proteins by analytical ultracentrifugation: Strategies and application to model systems. Biophys i. 2002;82(2):1096-1111. (Pubitemid 34111246)
31. Samavedam R, Morrison R, Kichefski T, Cote 5, Rathore AS. Lifetime studies for membrane reuse: principles and case study. BioPharm Int. 2007;20(9):48-54. (Pubitemid 47573234)
32. Rathore AS, Sofer GS. Lifespan studies for chromatography and filtration media. In: Rathore AS, Sofer GS, editors. Process Validation. Marcel Dekker; 2005. p. 169-203.